PPARA and metabolic dysfunction-associated steatotic liver disease: Furthermore, a previous study has explored the pharmacological network of DSS in ALD and NAFLD and found that PPARα, an important fatty acid β-oxidation-related gene in NAFLD, is one of the hepatoprotective targets of DSS (Hong et al., 2017).